Monday, January 22, 2018
 
 
Company News: Page (1) of 1 - 01/02/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
BioCorRx CEO, Brady Granier, Appears on Fox & Friends to Discuss the Opioid Epidemic

(January 02, 2018)

ANAHEIM, CA, Jan. 02, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that Brady Granier, BioCorRx CEO, President, and Director, appeared as a guest on Fox & Friends to discuss the BioCorRx® Recovery Program and the naltrexone implant for the treatment of opioid use disorder. The segment can be viewed online at: https://www.biocorrx.com/news-media/media.

Fox & Friends is a daily morning news/talk program airing on Fox News Channel. It begins at 6:00 a.m. Eastern Time with the latest Fox News Live headlines and news of the morning and continues with a variety of segments including current events, interviews, updates of news stories with correspondents, political analysis from the hosts, and entertainment segments.

About BioCorRx

BioCorRx Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing injectable and implantable naltrexone products for potential future regulatory approval. For more information on BICX, visit www.BioCorRx.com.



Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.

CONTACT: BioCorRx [email protected] Relations:Crescendo Communications, LLC(212) 671-1020 [email protected]

Page: 1


Related Keywords:
Related Sites: Hollywood Industry ,   DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
 
 
 
 
 





Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines